21 Dermatology CRO and CDMO vendors

It depends on the indication. Psoriasis work most often runs through the imiquimod-induced mouse model with epidermal thickness and inflammatory cytokine readouts. Atopic dermatitis commonly uses oxazolone or DNFB sensitization models. Acne, wound healing, fibrosis, and pigmentation each have their own established systems. Alongside the in vivo models, human skin explants and 3D reconstructed epidermis (such as EpiDerm or EpiSkin) cover barrier, irritation, and early efficacy questions without an animal. The practical advice is to ask whether the CRO already has your specific model validated in-house with historical control data, rather than building it for the first time on your dollar.

Usually yes, because skin-applied and many systemic dermatology drugs reach sun-exposed tissue. The common package is an in vitro 3T3 NRU phototoxicity assay as a first screen, followed where indicated by in vivo phototoxicity and photoallergy work, run against ICH S10 guidance on photosafety evaluation. Compounds that absorb light in the relevant range, distribute to skin or eye, or are applied topically are the ones that trigger the assessment. Confirm with the CRO whether a given study is exploratory or regulatory-grade, since paying GLP prices for an early screen, or filing an exploratory result a reviewer expects in GLP, are both avoidable mistakes.

Most derm trials are scored on validated clinician-rated scales: PASI and IGA for psoriasis, EASI and IGA for atopic dermatitis, lesion counts and IGA for acne, plus indication-specific tools for vitiligo, alopecia, and hidradenitis. Patient-reported measures (DLQI, itch NRS) usually run alongside. Because these scores are visual and subjective, inter-rater and intra-rater drift directly inflates variance and can wash out a real treatment effect. That is why grader training, re-calibration, and central reads of standardized photography are not administrative niceties. They protect the statistical power you are paying a CRO to deliver, so weight a vendor's grading and imaging discipline heavily when you choose.

Quite different in where the work concentrates. A topical generic (ANDA) leans on demonstrating sameness to the reference product: Q1 and Q2 (same components and concentrations), Q3 microstructure and physical characterization, IVRT, and often an IVPT or a comparative clinical endpoint study, all aligned to FDA product-specific guidance for that drug. A 505(b)(2) sits between, reusing some reference data while adding bridging studies. A novel dermatology drug runs the full discovery-through-clinical path with its own efficacy and safety package. Match the CRO to the pathway, because the regulatory expectations and the critical-path studies are not the same, and a lab fluent in one is not automatically fluent in the others.

Often yes, because the best specialists rarely cover all three equally well. A typical topical program might use a skin-model and dermatopharmacokinetics CRO for permeation and IVPT, a semisolid CDMO for the cream or gel and its GMP clinical supply, and a clinical CRO with real derm site access for the trial. Contracting and paying each one separately is the friction. Through BioBridgeX you can source and coordinate multiple dermatology vendors under one contract, one purchase order, and one invoice, with BioBridgeX acting as the neutral vendor of record.

BioBridgeX is a neutral vendor of record, not a lab, so it has no incentive to steer your permeation work or clinical study toward a preferred site. You describe the work (route, indication, the specific services, and timeline) and get matched with qualified dermatology CRO and CDMO vendors, then compare them on capability, relevant experience, and transparent quotes in one view. A derm program often pulls in several vendors, a skin-model CRO, a dermatopharmacokinetics lab, a semisolid CDMO, and a clinical CRO, and instead of papering a separate agreement with each, you contract once: one contract, one PO, and one invoice across all of them. It is free for buyers, vendors pay a flat 2% fee, and coverage spans every indication and modality, so the same account carries forward as your program advances.